Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.

International journal of cancer - 15 Jun 2017

Martinez Vanesa G, Crown John, Porter Richard K, O'Driscoll Lorraine

Abstract excerpt

Neuromedin U (NmU) is a neuropeptide belonging to the neuromedin family. Recently, we reported a significant association between NmU and breast cancer, particularly correlating with increased aggressiveness, resistance to HER2-targeted therapies and overall significantly poorer outcome for patients, although the mechanism through which it exerts this effect remained unexplained. Investigating this, here we found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Energy Metabolism

Share to Epithelial-Mesenchymal Transition

Share to Immunoblotting

Share to Neoplastic Stem Cells

Share to Neuropeptides

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 28340506
DOI: 10.1002/ijc.30705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.PMID 28340506Read ↗

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.Semantic proximity Read ↗

Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancerSemantic proximity Read ↗

Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem CellsSemantic proximity Read ↗

2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotypeSemantic proximity Read ↗

ETV4 promotes breast cancer cell stemness by activating glycolysis and CXCR4-mediated sonic Hedgehog signalingSemantic proximity Read ↗

Biglycan Promotes Cancer Stem Cell Properties, NFκB Signaling and Metastatic Potential in Breast Cancer CellsSemantic proximity Read ↗

LC-mHTT-AN2 oversees lactate transport, hypoxia, and glucose homeostasis through dual regulation of MCT-1/4 in the tumor microenvironmentSemantic proximity Read ↗

A multiOmics approach to identify altered ion channels across breast cancer subtypesSemantic proximity Read ↗

Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor.Semantic proximity Read ↗

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination.Semantic proximity Read ↗

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancerSemantic proximity Read ↗

Proteomic Characterization of a 3D HER2+ Breast Cancer Model Reveals the Role of Mitochondrial Complex I in Acquired Resistance to TrastuzumabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.